

臺灣地區鮑氏不動桿菌臨床分離株對Imipenem抗藥機制的研究 = Mechanisms of imipenem resistance in acinetobacter baumannii ..

王思博、劉淑瑛；邱政洵

E-mail: 9708034@mail.dyu.edu.tw

摘要

鮑氏不動桿菌 (*Acinetobacter baumannii*) 為人體常在菌，也是目前院內感染最常被分離出菌種之一。本實驗為了研究這些*A. baumannii*分離菌株之相關抗藥機制，主要利用PCR技術、metallo- β -lactamases偵測技術、一維、二維蛋白電泳、南方墨點法及紙錠擴散法 (E-test) 來鑑定及分析。經由紙錠擴散法(E-test) 發現有16株對於imipenem抗生素呈現抗藥性，包含7株帶有blaIMP-1抗藥基因，MIC均大於32 μ g/ml。另一方面用Kado-Liu方法抽取質體做南方墨點法也發現，blaIMP-1抗藥基因位於*A. baumannii*大質體上。因此，推測攜帶有blaIMP-1抗藥基因之菌株可能藉由質體來相互傳播。另外9株對imipenem呈現誘導性抗藥 (inducible resistance)，因其MIC介於8~32 μ g/ml，而且其抑制圈內有散在性菌落。利用PCR實驗偵測結果發現這些菌株不帶有blaIMP-1、blaVIM、blaOXA-23或blaOXA-24抗藥基因，metallo- β -lactamase篩選也呈陰性反應。誘導性菌株以不同濃度imipenem培養 (0, 16, 32 μ g/ml) 後，以一維蛋白電泳及MALDI-TOF MS 分析發現AmpC蛋白質表現量會因imipenem濃度愈多而增加，此AmpC蛋白質經比對後發現屬於blaADC-1類別抗藥基因產物。根據序列比對發現為新的ADC抗藥基因，將之命名為blaADC-29。同時也發現誘導性抗藥菌株高達85% 比例皆攜帶有blaADC-29與上游的ISAba1基因，推測ISAba1可能與造成AmpC蛋白質大量表現有相關性。以南方吸漬法證實blaADC-29位於染色體上，而blaIMP-1則位於質體上。當以即時定量聚合 γ -連鎖反應偵測誘導性抗藥菌株blaADC-29、ompA及adeB之表現量時，發現blaADC-29及ompA表現量會隨著imipenem之濃度增加而增加，然而與efflux pump 相關的 adeB基因之表現量卻不受影響。本研究結果顯示鮑氏不動桿菌可能會因為攜帶抗藥基因blaADC-29與其上游的ISAba1，並藉由blaADC-29的高度表現而造成對imipenem具有誘導性抗藥，因此臨床上過度使用imipenem會促進該菌誘導性抗藥的表現。在病人臨床資料比對分析結果發現，使用imipenem抗生素在分別帶有carbapenem 敏感 (SS) 與非敏感 (包括SR 及 RR) 菌株之兩組病人的治療上，其用藥平均天數具統計差異性。

關鍵詞：多重抗藥性鮑氏不動桿菌；乙內醯胺 β -內酰胺酶；誘導性抗藥；亞胺培南

目錄

目錄 封面內頁 簽名頁 授權書.....	iii 中文摘要.....
..... iv 英文摘要.....	vi 誌謝.....
..... viii 目錄.....	x 圖目錄.....
..... xiii 表目錄.....	xv 1. 緒論 1.1
Acinetobacter baumannii 簡介 1.1.1 鮑氏不動桿菌之生物特性及其感染臨床表徵 1.1.2 β -內酰胺酶的抗藥機制.....	2 1.1.3 鮑氏不動桿菌乙內醯胺 β -內酰胺酶分類..... 3 1.1.4 鮑氏不動桿菌外膜蛋白於抗藥機制之相關研究 5 1.2 抗藥基因ADC之簡介..... 6 1.3 即時定量聚合 γ -連鎖反應..... 7 1.4 實驗動機及目的..... 8 2. 材料與方法 2.1 菌株來源及分群..... 9 2.2 Genomic DNA萃取..... 9 2.3 聚合 γ -連鎖反應 (PCR)..... 9 2.4 純化PCR產物..... 10 2.5 抗生素敏感性測試 (E-test and disk diffusion test)..... 10 2.5.1 抗生素敏感性測試E-test 測試法..... 10 2.6 誘導性菌株不加藥培養7天後Imipenem敏感性分析. 11 2.7 鮑氏不動桿菌metallo- β -lactamase分析..... 11 2.8 快速質體分析 (Kado-Liu)..... 12 2.9 南方墨點法 2.9.1 轉印及固定..... 13 2.9.2 探針之製備..... 14 2.9.3 雜合與顯影..... 14 2.10 一維蛋白電泳 2.10.1 β -內酰胺酶外膜蛋白之製備..... 15 2.10.2 製膠與一維蛋白電泳分析..... 16 2.10.3 銀染及切膠純化..... 17 2.10.4 MALDI-TOF MS胺基酸序列分析暨資料庫比對..... 18 2.10.4.1 In gel digestion..... 18 2.10.4.2 MALDI-TOF MS analysis..... 18 2.11 二維蛋白電泳..... 19 2.11.1 β -內酰胺酶外膜蛋白之製備..... 19 2.11.2 製膠與二維蛋白電泳分析..... 20 2.12 抗藥基因ADC之定序..... 21 2.13 Total RNA萃取..... 22 2.14 製備cDNA (reverse transcription)..... 23 2.15 即時定量聚合 γ -連鎖反應..... 23 2.16 長庚病人病歷比對資料分析..... 24 3. 結果與討論 3.1 聚合 γ -連鎖反應 (PCR)..... 26 3.2 抗生素敏感性測試..... 27 3.3 2004、2006年菌株測試metallo- β -lactamase..... 28 3.4 誘導性菌株不加藥培養7天後imipenem敏感

性之測試.....	29	3.5 南方墨點法.....	30
3.6 一維蛋白電泳.....	30	3.7 二維蛋白電泳.....	32
3.8 抗藥基因ADC之定序.....	32	3.9 即時定量聚合?連鎖反應.....	33
3.10 長庚病人病歷比對資料分析.....	34	4. 結論.....	37
.....	68	附錄.....	73
圖目錄 圖1. 抗生素E-test敏感性測試.....	38	圖2. 2004年菌株PCR測試blaIMP-1抗藥基因.....	39
圖3. 2004年菌株測試有無含鋅類 內醯銨?.....	40	圖4. 誘導性菌株不加藥物培養後在第1,2,4,8天用E-test測試對imipenem敏感性.....	41
圖5. 南方墨點法測試blaIMP-1抗藥基因.....	42	圖6. 南方墨點法測試blaAmpC抗藥基因.....	43
圖7. 誘導性抗藥菌株Ab-19、Ab-20和Ab-28用不同濃度imipenem (0,16,32 μg/ml) 培養後進行一維蛋白電泳 膠分析圖.....	44	圖8. 誘導性抗藥菌株Ab-20在 (i) 不加imipenem (ii) 以 32 μg/ml imipenem培養後進行二?蛋白電泳膠分析圖... 46	46
圖9. 抗藥基因blaADC-29序列比對, 主要以blaADC-1 group序列 為主.....	47	圖10. 抗藥基因blaADC-29以DNA序列進行演化圖分析, blaADC-29 屬於ADC-1 group.....	47
圖11. 抗藥基因blaADC-29 以蛋白質序列進行演化圖分析, blaADC-29屬於ADC-1 group.....	48	圖12. 抗藥基因blaADC-29與其它ADC-1 group的bla基因DNA 序列比對圖。.....	49
圖13. Q-PCR測試blaADC-29抗藥基因表量.....	52	圖14. Q-PCR測試外膜蛋白ompA 表現量.....	53
圖15. Q-PCR測試efflux pump adeB 基因表現量.....	54	表目錄 表1. PCR引子序列設計.....	55
表2. 2004年菌株E-test、metallo- -lactamase、PCR測試結果 56	56	表3. 2004年菌株PCR測試是否含有其他抗藥基因.....	57
表4. 2006菌株測試metallo- -lactamase、PCR、E-test測試結果.....	58	表5. 對imipenem呈現誘導性的菌株不加藥物培養7天後測 試對imipenem敏感性.....	60
表6. blaADC引子序列設計.....	61	表7. 一維與二?蛋白電泳比對結果.....	62
表8. 二?蛋白電泳比對結果.....	63	表9. 細菌在治療中敏感性發生變化SS與SR的病人的臨床因 子分析.....	64
表10. 比較以下各種抗生素使用平均天數於SS和SR組是否 有差異... ..	65	表11. Q-PCR引子序列設計.....	66
表12. PCR測試blaADC-29、ompA、adeB表現量挑選菌株特性 67	67		

參考文獻

1. 蔡文誠。2002。"微生物學"。27:517-519
2. 潘彥如、林敬哲。2003。"科儀新知"。26(6):6-16
3. 曾麗芸。2006。抗藥性鮑氏不動桿菌對ciprofloxacin及imipenem之抗藥性機制分析。私立大葉大學分子生物科技學研究所碩士論文, 彰化。
4. Arakawa, Y., N. Shibata, K. Shibayama, H. Kurokawa, T. Yagi, H. Fujiwara, and M. Goto. 2000. Convenient test for screening metallo-beta-lactamase-producing gram-negative bacteria by using thiol compounds. *J Clin Microbiol* 38:40-3.
5. Baker, P. J., R. T. Evans, J. Slots, and R. J. Genco. 1985. Antibiotic susceptibility of anaerobic bacteria from the human oral cavity. *J Dent Res* 64:1233-44.
6. Beceiro, A., F. J. Perez-Llarena, A. Perez, M. Tomas Mdel, A. Fernandez, S. Mallo, R. Villanueva, and G. Bou. 2007. Molecular characterization of the gene encoding a new AmpC beta-lactamase in *Acinetobacter baylyi*. *J Antimicrob Chemother* 59:996-1000.
7. Bergogne-Berezin, E., and K. J. Towner. 1996. *Acinetobacter* spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. *Clin Microbiol Rev* 9:148-65.
8. Bou, G., G. Cervero, M. A. Dominguez, C. Quereda, and J. Martinez- Beltran. 2000. Characterization of a nosocomial outbreak caused by a multiresistant *Acinetobacter baumannii* strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in *A. baumannii* is not due solely to the presence of beta-lactamases. *J Clin Microbiol* 38:3299-305.
9. Bou, G., G. Cervero, M. A. Dominguez, C. Quereda, and J. Martinez- Beltran. 2000. PCR-based DNA fingerprinting (REP-PCR, AP-PCR) and pulsed- field gel electrophoresis characterization of a nosocomial outbreak caused by imipenem- and meropenem-resistant *Acinetobacter baumannii*. *Clin Microbiol Infect* 6:635-43.
10. Bou, G., A. Oliver, and J. Martinez-Beltran. 2000. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an *Acinetobacter baumannii* clinical strain. *Antimicrob Agents Chemother* 44:1556-61.
11. Brown, S., and S. Amyes. 2006. OXA (beta)-lactamases in *Acinetobacter*: the story so far. *J Antimicrob Chemother* 57:1-3.
12. Brown, S., and S. G. Amyes. 2005. The sequences of seven class D beta- lactamases isolated from carbapenem-resistant *Acinetobacter baumannii* from four continents. *Clin Microbiol Infect* 11:326-9.
13. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for beta-lactamases and its correlation with molecular structure. *Antimicrob Agents Chemother* 39:1211-33.
14. Bush, L. M., J. Calmon, and C. C. Johnson. 1995. Newer penicillins and beta- lactamase inhibitors. *Infect Dis Clin North Am* 9:653-86.
15. Dalla-Costa, L. M., J. M. Coelho, H. A. Souza, M. E. Castro, C. J. Stier, K. L. Bragagnolo, A. Rea-Neto, S. R. Penteado-Filho, D. M. Livermore, and N. Woodford. 2003. Outbreak of carbapenem-resistant *Acinetobacter baumannii* producing the OXA-23 enzyme in Curitiba, Brazil. *J Clin Microbiol* 41:3403-6.
16. Damier-Piolle, L., S. Magnet, S. Bremont, T. Lambert, and P. Courvalin. 2008. AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 52:557- 62.
17. del Mar Tomas, M., A. Beceiro, A. Perez, D. Velasco, R. Moure, R. Villanueva, J. Martinez-Beltran, and G. Bou. 2005. Cloning and functional analysis of the gene encoding the 33- to 36-kilodalton outer membrane protein associated with carbapenem resistance in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 49:5172-5.
18. Gehrlein, M., H.

Leying, W. Cullmann, S. Wendt, and W. Opferkuch. 1991. Imipenem resistance in *Acinetobacter baumannii* is due to altered penicillin-binding proteins. *Chemotherapy* 37:405-12.

19. Gribun, A., Y. Nitzan, I. Pechatnikov, G. Hershkovits, and D. J. Katcoff. 2003. Molecular and structural characterization of the HMP-AB gene encoding a pore-forming protein from a clinical isolate of *Acinetobacter baumannii*. *Curr Microbiol* 47:434-43.

20. Heritier, C., L. Poirel, and P. Nordmann. 2006. Cephalosporinase over-expression resulting from insertion of ISAb1 in *Acinetobacter baumannii*. *Clin Microbiol Infect* 12:123-30.

21. Hu, W. S., S. M. Yao, C. P. Fung, Y. P. Hsieh, C. P. Liu, and J. F. Lin. 2007. An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 51:3844-52.

22. Huang, S. S., S. C. Lee, N. Lee, L. C. See, M. H. Tsai, and W. B. Shieh. 2007. Comparison of in vitro activities of levofloxacin, ciprofloxacin, ceftazidime, cefepime, imipenem, and piperacillin-tazobactam against aerobic bacterial pathogens from patients with nosocomial infections. *J Microbiol Immunol Infect* 40:134-40.

23. Hujer, K. M., N. S. Hamza, A. M. Hujer, F. Perez, M. S. Helfand, C. R. Bethel, J. M. Thomson, V. E. Anderson, M. Barlow, L. B. Rice, F. C. Tenover, and R. A. Bonomo. 2005. Identification of a new allelic variant of the *Acinetobacter baumannii* cephalosporinase, ADC-7 beta-lactamase: defining a unique family of class C enzymes. *Antimicrob Agents Chemother* 49:2941-8.

24. Jeong, S. H., I. K. Bae, K. O. Park, Y. J. An, S. G. Sohn, S. J. Jang, K. H. Sung, K. S. Yang, K. Lee, D. Young, and S. H. Lee. 2006. Outbreaks of imipenem-resistant *Acinetobacter baumannii* producing carbapenemases in Korea. *J Microbiol* 44:423-31.

25. Kado, C. I., and S. T. Liu. 1981. Rapid procedure for detection and isolation of large and small plasmids. *J Bacteriol* 145:1365-73.

26. Kraniotaki, E., R. Manganelli, E. Platsouka, A. Grossato, O. Paniara, and G. Palu. 2006. Molecular investigation of an outbreak of multidrug-resistant *Acinetobacter baumannii*, with characterisation of class 1 integrons. *Int J Antimicrob Agents* 28:193-9.

27. Liu, S. Y., J. Y. Lin, C. Chu, L. H. Su, T. Y. Lin, and C. H. Chiu. 2006. Integron-associated imipenem resistance in *Acinetobacter baumannii* isolated from a regional hospital in Taiwan. *Int J Antimicrob Agents* 27:81-4.

28. Marti, S., J. Sanchez-Cespedes, E. Oliveira, D. Bellido, E. Giral, and J. Vila. 2006. Proteomic analysis of a fraction enriched in cell envelope proteins of *Acinetobacter baumannii*. *Proteomics* 6 Suppl 1:S82-7.

29. Nitzan, Y., I. Pechatnikov, D. Bar-El, and H. Wexler. 1999. Isolation and characterization of heat-modifiable proteins from the outer membrane of *Porphyromonas asaccharolytica* and *Acinetobacter baumannii*. *Anaerobe* 5:43-50.

30. Peleg, A. Y., J. Adams, and D. L. Paterson. 2007. Tigecycline Efflux as a mechanism for nonsusceptibility in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 51:2065-9.

31. Quale, J., S. Bratu, J. Gupta, and D. Landman. 2006. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of *Pseudomonas aeruginosa* clinical isolates. *Antimicrob Agents Chemother* 50:1633-41.

32. Seifert, H., R. Baginski, A. Schulze, and G. Pulverer. 1993. Antimicrobial susceptibility of *Acinetobacter* species. *Antimicrob Agents Chemother* 37:750-3.

33. Seifert, H., R. Baginski, A. Schulze, and G. Pulverer. 1993. The distribution of *Acinetobacter* species in clinical culture materials. *Zentralbl Bakteriol* 279:544-52.

34. Siroy, A., V. Molle, C. Lemaitre-Guillier, D. Vallenet, M. Pestel-Caron, A. J. Cozzone, T. Jouenne, and E. De. 2005. Channel formation by CarO, the carbapenem resistance-associated outer membrane protein of *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 49:4876-83.

35. Sung, J. Y., K. C. Kwon, J. W. Park, Y. S. Kim, J. M. Kim, K. S. Shin, J. W. Kim, C. S. Ko, S. Y. Shin, J. H. Song, and S. H. Koo. 2008. Dissemination of IMP-1 and OXA type beta-lactamase in carbapenem-resistant *Acinetobacter baumannii*. *Korean J Lab Med* 28:16-23.

36. Takahashi, A., S. Yomoda, I. Kobayashi, T. Okubo, M. Tsunoda, and S. Iyobe. 2000. Detection of carbapenemase-producing *Acinetobacter baumannii* in a hospital. *J Clin Microbiol* 38:526-9.

37. Thomson, J. M., and R. A. Bonomo. 2005. The threat of antibiotic resistance in Gram-negative pathogenic bacteria: beta-lactams in peril! *Curr Opin Microbiol* 8:518-24.

38. Van Looveren, M., and H. Goossens. 2004. Antimicrobial resistance of *Acinetobacter* spp. in Europe. *Clin Microbiol Infect* 10:684-704.

39. Walzer, G., E. Rosenberg, and E. Z. Ron. 2006. The *Acinetobacter* outer membrane protein A (OmpA) is a secreted emulsifier. *Environ Microbiol* 8:1026-32.

40. Yu, Y. S., Q. Yang, X. W. Xu, H. S. Kong, G. Y. Xu, and B. Y. Zhong. 2004. Typing and characterization of carbapenem-resistant *Acinetobacter calcoaceticus-baumannii* complex in a Chinese hospital. *J Med Microbiol* 53:653-6.